Pharmacyte Biotech Inc Financials
This page shows Pharmacyte Biotech Inc (PMCB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
PharmaCyte’s reported profit is balance-sheet driven, while the underlying business still behaves like a cash-burning development program.
FY2025 net income of$30.7M did not translate into self-funding, because operating cash flow was still-$3.0M and the company remained in an operating loss. From FY2023 to FY2025, cash fell from$74.7M to$13.2M as liabilities were cut sharply, which makes the profit look more like a balance-sheet event than evidence that the core business now funds itself.
The cost structure has flipped: R&D exceeded SG&A in FY2021, but by FY2025 SG&A was
Even after the cash drawdown, the balance sheet is still liquid: cash of
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Pharmacyte Biotech Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Pharmacyte Biotech Inc carries a low D/E ratio of 0.03, meaning only $0.03 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 18.01, Pharmacyte Biotech Inc holds $18.01 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Pharmacyte Biotech Inc earns a strong 70.3% return on equity (ROE), meaning it generates $70 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 85/100. This is up from 0.7% the prior year.
Pharmacyte Biotech Inc passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Pharmacyte Biotech Inc generates $-0.10 in operating cash flow (-$3.0M OCF vs $30.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Pharmacyte Biotech Inc generated $0 in revenue in fiscal year 2025.
Pharmacyte Biotech Inc reported $30.7M in net income in fiscal year 2025. This represents an increase of 9085.0% from the prior year.
Pharmacyte Biotech Inc earned $3.19 per diluted share (EPS) in fiscal year 2025. This represents an increase of 277.2% from the prior year.
Cash & Balance Sheet
Pharmacyte Biotech Inc held $13.2M in cash against $0 in long-term debt as of fiscal year 2025.
Pharmacyte Biotech Inc had 7M shares outstanding in fiscal year 2025. This represents a decrease of 11.9% from the prior year.
Margins & Returns
Pharmacyte Biotech Inc's ROE was 70.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 69.6 percentage points from the prior year.
Capital Allocation
Pharmacyte Biotech Inc invested $438K in research and development in fiscal year 2025. This represents an increase of 7.6% from the prior year.
Pharmacyte Biotech Inc spent $2.5M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 91.0% from the prior year.
PMCB Income Statement
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | N/A | $0 | $0 | $0 | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $93K-34.0% | $141K+48.3% | $95K | N/A | $118K+21.3% | $97K+1.5% | $96K | N/A |
| SG&A Expenses | $2.0M+64.0% | $1.2M+64.0% | $753K | N/A | $842K-16.5% | $1.0M-14.0% | $1.2M | N/A |
| Operating Income | -$2.1M-53.9% | -$1.4M-62.2% | -$848K | N/A | -$960K+13.2% | -$1.1M+12.8% | -$1.3M | N/A |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | $747K+110.1% | -$7.4M+11.3% | -$8.4M | N/A | -$3.0M-107.2% | -$1.5M-106.3% | $23.4M | N/A |
| EPS (Diluted) | $-0.17+86.3% | $-1.24-0.8% | $-1.23 | N/A | $-0.44-12.8% | $-0.39-120.5% | $1.90 | N/A |
PMCB Balance Sheet
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $55.9M-0.2% | $56.0M+24.1% | $45.1M-18.2% | $55.2M+25.9% | $43.8M-20.5% | $55.1M-21.5% | $70.2M+17.2% | $59.9M |
| Current Assets | $20.7M-10.1% | $23.0M+20.5% | $19.1M-14.6% | $22.4M+31.9% | $17.0M-20.5% | $21.3M-35.1% | $32.9M-34.8% | $50.4M |
| Cash & Equivalents | $20.2M+30.9% | $15.4M+16.9% | $13.2M-13.1% | $15.2M-7.4% | $16.4M-21.4% | $20.8M-36.1% | $32.6M-35.0% | $50.2M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $16.5M-15.2% | $19.4M+1178.7% | $1.5M-53.7% | $3.3M-8.4% | $3.6M-69.3% | $11.6M-32.1% | $17.2M-15.9% | $20.4M |
| Current Liabilities | $1.7M+6.4% | $1.6M+48.7% | $1.1M-63.6% | $2.9M+144.0% | $1.2M-75.0% | $4.8M-36.1% | $7.5M+0.7% | $7.4M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $38.1M+8.2% | $35.2M-19.2% | $43.6M-16.0% | $51.9M+28.9% | $40.3M-7.4% | $43.5M-8.9% | $47.7M+72.6% | $27.6M |
| Retained Earnings | -$100.0M+0.7% | -$100.7M-7.9% | -$93.3M-9.8% | -$85.0M+12.1% | -$96.7M-3.3% | -$93.7M-1.6% | -$92.2M+20.3% | -$115.6M |
PMCB Cash Flow Statement
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$787K+19.7% | -$980K+50.9% | -$2.0M-91.7% | -$1.0M-104.0% | -$510K+51.7% | -$1.1M-182.5% | -$373K-12.1% | -$333K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $5.0M+266.7% | -$3.0M | $0 | $0 | $0 | $0+100.0% | -$7.0M | $0 |
| Financing Cash Flow | $544K-91.2% | $6.2M | $0+100.0% | -$172K+95.7% | -$3.9M+63.3% | -$10.7M-5.6% | -$10.2M+4.9% | -$10.7M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | $402K | $0 | $0-100.0% | $172K-23.8% | $225K-84.0% | $1.4M+89.1% | $742K-36.8% | $1.2M |
PMCB Financial Ratios
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | 2.0%+23.0pp | -21.1%-1.9pp | -19.2% | N/A | -7.6%-4.2pp | -3.4%-52.5pp | 49.1% | N/A |
| Return on Assets | 1.3%+14.6pp | -13.3%+5.3pp | -18.5% | N/A | -7.0%-4.3pp | -2.7%-36.0pp | 33.4% | N/A |
| Current Ratio | 12.33-2.3 | 14.60-3.4 | 18.01+10.3 | 7.68-6.5 | 14.20+9.7 | 4.47+0.1 | 4.40-2.4 | 6.80 |
| Debt-to-Equity | 0.43-0.1 | 0.55+0.5 | 0.03-0.0 | 0.06-0.0 | 0.09-0.2 | 0.27-0.1 | 0.36-0.4 | 0.74 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Pharmacyte Biotech Inc's annual revenue?
Pharmacyte Biotech Inc (PMCB) reported $0 in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Pharmacyte Biotech Inc profitable?
Yes, Pharmacyte Biotech Inc (PMCB) reported a net income of $30.7M in fiscal year 2025.
What is Pharmacyte Biotech Inc's return on equity (ROE)?
Pharmacyte Biotech Inc (PMCB) has a return on equity of 70.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Pharmacyte Biotech Inc's operating cash flow?
Pharmacyte Biotech Inc (PMCB) generated -$3.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Pharmacyte Biotech Inc's total assets?
Pharmacyte Biotech Inc (PMCB) had $45.1M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Pharmacyte Biotech Inc spend on research and development?
Pharmacyte Biotech Inc (PMCB) invested $438K in research and development during fiscal year 2025.
What is Pharmacyte Biotech Inc's current ratio?
Pharmacyte Biotech Inc (PMCB) had a current ratio of 18.01 as of fiscal year 2025, which is generally considered healthy.
What is Pharmacyte Biotech Inc's debt-to-equity ratio?
Pharmacyte Biotech Inc (PMCB) had a debt-to-equity ratio of 0.03 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Pharmacyte Biotech Inc's return on assets (ROA)?
Pharmacyte Biotech Inc (PMCB) had a return on assets of 68.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Pharmacyte Biotech Inc's cash runway?
Based on fiscal year 2025 data, Pharmacyte Biotech Inc (PMCB) had $13.2M in cash against an annual operating cash burn of $3.0M. This gives an estimated cash runway of approximately 53 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Pharmacyte Biotech Inc's Piotroski F-Score?
Pharmacyte Biotech Inc (PMCB) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Pharmacyte Biotech Inc's earnings high quality?
Pharmacyte Biotech Inc (PMCB) has an earnings quality ratio of -0.10x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Pharmacyte Biotech Inc?
Pharmacyte Biotech Inc (PMCB) scores 47 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.